Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: Application to antibody tumour uptake studies

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 9, 2007, Pages 1376-1387

  Fortin, Marc André ^a,b   Salnikov, Alexei V ^c,d   Nestor, Marika ^e   Heldin, Nils Erik ^b   Rubin, Kristofer ^c   Lundqvist, Hans ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anaplastic thyroid carcinoma; CD44v6; Positron emission tomography; Radioimmunodiagnostics; Tumour interstitial fluid pressure

Indexed keywords

IODINE; MONOCLONAL ANTIBODY U36 I 124; RADIOPHARMACEUTICAL AGENT; SODIUM IODIDE SYMPORTER; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIOACTIVITY; THYROID CARCINOMA; TISSUE PRESSURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CARCINOMA; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; IODINE RADIOISOTOPES; KINETICS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOASSAY; THYROID NEOPLASMS;

EID: 34548174214     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0346-5     Document Type: Article

References (55)

1. Van Hal NL, Van Dongen GA, Rood-Knippels EM, Van Der Valk P, Snow GB, Brakenhoff RH. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int J Cancer 1996;68:520-7.
2. Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 2004;53:567-79.
3. Figge J, del Rosario AD, Gerasimov G, Dedov I, Bronstein M, Troshina K, et al. Preferential expression of the cell adhesion molecule CD44 in papillary thyroid carcinoma. Exp Mol Pathol 1994;61:203-11.
4. Ermak G, Jennings T, Robinson L, Ross JS, Figge J. Restricted patterns of CD44 variant exon expression in human papillary thyroid carcinoma. Cancer Res 1996;56:1037-42.
5. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 1999;17:3494-502.
6. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-50.
7. Chhieng DC, Ross JS, McKenna BJ. CD44 immunostaining of thyroid fine-needle aspirates differentiates thyroid papillary carcinoma from other lesions with nuclear grooves and inclusions. Cancer 1997;81:157-62.
8. Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn Cytopathol 2004;31:392-6.
9. Nasir A, Catalano E, Calafati S, Cantor A, Kaiser HE, Coppola D. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. In Vivo 2004;18:189-95.
10. Gu J, Daa T, Kashima K, Yokoyama S, Nakayama I, Noguchi S. Expression of splice variants of CD44 in thyroid neoplasms derived from follicular cells. Pathol Int 1998;48:184-90.
11. Aogi K, Kitahara K, Urquidi V, Tarin D, Goodison S. Comparison of telomerase and CD44 expression as diagnostic tumor markers in lesions of the thyroid. Clin Cancer Res 1999;5:2790-7.
12. Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993;53:4383-90.
13. Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003;18:655-61.
14. 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging 2004;31:1645-52.
15. Gullino PM, Clark SH, Grantham FH. The interstitial fluid of solid tumors. Cancer Res 1964;24:780-94.
16. Wiig H, Tveit E, Hultborn R, Reed RK, Weiss L. Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scand J Clin Lab Invest 1982;42:159-64.
17. Phillips RM, Bibby MC, Double JA. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst 1990;82:1457-68.
18. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-51.
19. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
20. Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, Koteliansky VE, et al. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999;84:1212-22.
21. Lammerts E, Roswall P, Sundberg C, Gotwals PJ, Koteliansky VE, Reed RK, et al. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int J Cancer 2002;102:453-62.
22. Dahlman T, Lammerts E, Bergström D, Franzen A, Westermark K, Heldin NE, et al. Collagen type I expression in experimental anaplastic thyroid carcinoma: regulation and relevance for tumorigenicity. Int J Cancer 2002;98:186-92.
23. Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin NE, Rubin K. Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 2005;85:512-21.
24. Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
25. Ain KB, Taylor KD. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 1994;78:1097-102.
26. Nestor M, Persson M, Cheng J, Tolmachev V, van Dongen G, Anniko M, et al. Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods. Bioconjug Chem 2003;14:805-10.
27. Nestor M, Persson M, van Dongen GA, Jensen HJ, Lundqvist H, Anniko M, et al. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2005;32:1296-1304.
28. Auffray C, Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem 1980;107:303-14.
29. Heldin NE, Westermark B. Epidermal growth factor, but not thyrotropin, stimulates the expression of c-fos and c-myc messenger ribonucleic acid in porcine thyroid follicle cells in primary culture. Endocrinology 1988;122:1042-6.
30. http://osem-pet-spect.org
31. ASIPro VM [ http://www.concorde.ctimi.com ].
32. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002;43:1188-200.
33. 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001;28:639-45.
34. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003;24:48-77.
35. Grünwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
36. Lind P, Kumnig G, Matschnig S, Heinisch M, Gallowitsch HJ, Mikosch P, et al. The role of F-18FDG PET in thyroid cancer. Acta Med Austriaca 2000;27:38-41.
37. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797-804.
38. Jadvar H, Fischman AJ. Evaluation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography. Clin Positron Imaging 1999;2:153-8.
39. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993;114:728-34; discussion 34-5.
40. Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312-9.
41. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342-8.
42. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002;43:66-71.
43. Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 2005;12:254-60.
44. Netti PA, Hamberg LM, Babich JW, Kierstead D, Graham W, Hunter GJ, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 1999;96:3137-42.
45. Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, et al. Effect of platelet-derived growth factor receptor-b inhibition with STI571 on radioimmunotherapy. Cancer Res 2005;65:7824-31.
46. Kristjansen PE, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 1993;53:4764-6.
47. Zlotecki RA, Baxter LT, Boucher Y, Jain RK. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc Res 1995;50:429-43.
48. Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 1996;74:533-6.
49. Brekken C, de Lange Davies C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett 1998;131:65-70.
50. Jacobson A, Salnikov A, Lammerts E, Roswall P, Sundberg C, Heldin P, et al. Hyaluronan content in experimental carcinoma is not correlated to interstitial fluid pressure. Biochem Biophys Res Commun 2003;305:1017-23.
51. 51Cr-EDTA. Int J Cancer 2000;86:636-43.
52. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
53. Hauck ML, Coffin DO, Dodge RK, Dewhirst MW, Mitchell JB, Zalutsky MR. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int J Hyperthermia 1997;13:307-16.
54. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004;31:18-23.
55. Spitzweg C, Joba W, Morris JC, Heufelder AE. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 1999;9:821-30.